Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
|Podcasts|March 21, 2023
Health Equity Conversations: Improving Diversity of Oncology Care Staff
Author(s)Matthew Gavidia
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
Advertisement
AJMC.com recently launched a resource center, the
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion (DEI) advancing health equity in their respective organization’s policy and practice initiatives, including:
- Terrance Mayes, EdD, associate director for DEI at the Stanford Cancer Institute, and inaugural chair of National Comprehensive Cancer Network's (NCCN) DEI Directors Forum
- Loretta Erhunmwunsee, MD, FACS, thoracic surgeon and an assistant professor in the Division of Thoracic Surgery, City of Hope National Medical Center, and inaugural vice-chair of NCCN's DEI Directors Forum
- Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.
Advertisement
Related to this article
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
3
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5